A later trial, using an alternative TNF-α-antagonist, sought to determine the efficacy of anti-TNF-α for the reduction of inflammation in a cohort of exacerbating COPD patients (114) with no clinical benefits. The gene discussed is TNF; the disease is chronic obstructive pulmonary disease.